82 related articles for article (PubMed ID: 24050021)
1. [Pharmacotherapy for schizophrenia: are newer drugs truly superior?].
Ohmori T
Seishin Shinkeigaku Zasshi; 2013; 115(7):774-81. PubMed ID: 24050021
[TBL] [Abstract][Full Text] [Related]
2. Antipsychotic monotherapy and adjuvant psychotropic therapies in schizophrenia patients: effect on time to readmission.
Valevski A; Gilat Y; Olfson M; Benaroya-Milshtein N; Weizman A
Int Clin Psychopharmacol; 2012 May; 27(3):159-64. PubMed ID: 22466059
[TBL] [Abstract][Full Text] [Related]
3. [Pharmacology and clinical implication of typical antipsychotics].
Ohmori T
Nihon Rinsho; 2013 Apr; 71(4):648-53. PubMed ID: 23678594
[TBL] [Abstract][Full Text] [Related]
4. Effects of first-generation antipsychotics versus second-generation antipsychotics on quality of life in schizophrenia: a double-blind, randomised study.
Gründer G; Heinze M; Cordes J; Mühlbauer B; Juckel G; Schulz C; Rüther E; Timm J;
Lancet Psychiatry; 2016 Aug; 3(8):717-729. PubMed ID: 27265548
[TBL] [Abstract][Full Text] [Related]
5. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia.
Lewis SW; Barnes TR; Davies L; Murray RM; Dunn G; Hayhurst KP; Markwick A; Lloyd H; Jones PB
Schizophr Bull; 2006 Oct; 32(4):715-23. PubMed ID: 16540702
[TBL] [Abstract][Full Text] [Related]
6. Time to rehospitalization in patients with schizophrenia discharged on first generation antipsychotics, non-clozapine second generation antipsychotics, or clozapine.
Werneck AP; Hallak JC; Nakano E; Elkis H
Psychiatry Res; 2011 Aug; 188(3):315-9. PubMed ID: 21596442
[TBL] [Abstract][Full Text] [Related]
7. Differential effects of clozapine versus other antipsychotics on clinical outcome and dopamine release in the brain.
Advokat C
Essent Psychopharmacol; 2005; 6(2):73-90. PubMed ID: 15765792
[TBL] [Abstract][Full Text] [Related]
8. Quality of life in the long-term treatment and the role of second-generation antipsychotics.
Mohr P
Neuro Endocrinol Lett; 2007 Feb; 28 Suppl 1():117-33. PubMed ID: 17262004
[TBL] [Abstract][Full Text] [Related]
9. First generation antipsychotics switch with Risperidone in the treatment of chronic schizophrenic patients.
Popović I; Ravanić D; Popović V; Vladejić S; Stanojević A; Stojanović M
Psychiatr Danub; 2011 Dec; 23(4):384-8. PubMed ID: 22075740
[TBL] [Abstract][Full Text] [Related]
10. Different serine and glycine metabolism in patients with schizophrenia receiving clozapine.
Hons J; Vasatova M; Cermakova E; Doubek P; Libiger J
J Psychiatr Res; 2012 Jun; 46(6):811-8. PubMed ID: 22502820
[TBL] [Abstract][Full Text] [Related]
11. A meta-analysis of the efficacy of second-generation antipsychotics.
Davis JM; Chen N; Glick ID
Arch Gen Psychiatry; 2003 Jun; 60(6):553-64. PubMed ID: 12796218
[TBL] [Abstract][Full Text] [Related]
12. Treatment pathway and patterns of clozapine prescribing for schizophrenia in New Zealand.
Wheeler AJ
Ann Pharmacother; 2008 Jun; 42(6):852-60. PubMed ID: 18477732
[TBL] [Abstract][Full Text] [Related]
13. Using antipsychotic agents in older patients.
Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
[TBL] [Abstract][Full Text] [Related]
14. Changes in neuroendocrine and metabolic hormones induced by atypical antipsychotics in normal-weight patients with schizophrenia.
Popovic V; Doknic M; Maric N; Pekic S; Damjanovic A; Miljic D; Popovic S; Miljic N; Djurovic M; Jasovic-Gasic M; Dieguez C; Casanueva FF
Neuroendocrinology; 2007; 85(4):249-56. PubMed ID: 17570902
[TBL] [Abstract][Full Text] [Related]
15. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).
Jones PB; Barnes TR; Davies L; Dunn G; Lloyd H; Hayhurst KP; Murray RM; Markwick A; Lewis SW
Arch Gen Psychiatry; 2006 Oct; 63(10):1079-87. PubMed ID: 17015810
[TBL] [Abstract][Full Text] [Related]
16. The METEOR study: frequency of metabolic disorders in patients with schizophrenia. Focus on first and second generation and level of risk of antipsychotic drugs.
Falissard B; Mauri M; Shaw K; Wetterling T; Doble A; Giudicelli A; De Hert M
Int Clin Psychopharmacol; 2011 Nov; 26(6):291-302. PubMed ID: 21876442
[TBL] [Abstract][Full Text] [Related]
17. What do large scale studies of medication in schizophrenia add to our management strategies?
Agius M; Davis A; Gilhooley M; Chapman S; Zaman R
Psychiatr Danub; 2010 Jun; 22(2):323-8. PubMed ID: 20562774
[TBL] [Abstract][Full Text] [Related]
18. The effectiveness of guideline implementation strategies on improving antipsychotic medication management for schizophrenia.
Owen RR; Hudson T; Thrush C; Thapa P; Armitage T; Landes RD
Med Care; 2008 Jul; 46(7):686-91. PubMed ID: 18580387
[TBL] [Abstract][Full Text] [Related]
19. Ethnic comparisons of antipsychotic use in schizophrenia.
Wheeler A; Humberstone V; Robinson E
Aust N Z J Psychiatry; 2008 Oct; 42(10):863-73. PubMed ID: 18777230
[TBL] [Abstract][Full Text] [Related]
20. Management of treatment-resistant patients with schizophrenia.
Marder SR
J Clin Psychiatry; 1996; 57 Suppl 11():26-30. PubMed ID: 8941168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
